4//SEC Filing
PATOU GARY 4
Accession 0000950170-23-070841
CIK 0001582313other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 5:38 PM ET
Size
26.2 KB
Accession
0000950170-23-070841
Insider Transaction Report
Form 4
PATOU GARY
Director
Transactions
- Exercise/Conversion
Common Shares
2023-12-13$9.85/sh+6,378$62,823→ 29,951 total - Exercise/Conversion
Common Shares
2023-12-13$9.85/sh+2,880$28,368→ 26,453 total - Tax Payment
Common Shares
2023-12-13$39.68/sh−1,278$50,711→ 28,673 total - Sale
Common Shares
2023-12-13$38.94/sh−5,100$198,594→ 23,573 total - Tax Payment
Common Shares
2023-12-13$39.68/sh−577$22,895→ 25,876 total - Sale
Common Shares
2023-12-13$39.10/sh−2,303$90,047→ 23,573 total - Tax Payment
Common Shares
2023-12-13$39.68/sh−1,167$46,307→ 27,550 total - Sale
Common Shares
2023-12-13$41.05/sh−7,598$311,898→ 4,902 total(indirect: See Note) - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-13−5,144→ 0 totalExercise: $9.00From: 2017-11-04Exp: 2024-11-03→ Common Shares (5,144 underlying) - Exercise/Conversion
Common Shares
2023-12-13$9.00/sh+5,144$46,296→ 28,717 total - Sale
Common Shares
2023-12-13$39.84/sh−3,977$158,444→ 23,573 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-13−6,378→ 0 totalExercise: $9.85From: 2016-12-31Exp: 2024-01-13→ Common Shares (6,378 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-13−2,800→ 0 totalExercise: $9.85From: 2016-12-31Exp: 2024-01-13→ Common Shares (2,800 underlying)
Footnotes (7)
- [F1]Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
- [F2]The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- [F3]Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- [F4]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F7]By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001283535
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 5:38 PM ET
- Size
- 26.2 KB